REQ-2024-012 Supplementary material

Table 1. Complementary patient's characteristics of IE treated with DBV.

Case/Age	IE Type and location	Microorganism	IE complications	Previous DBV treatment (weeks)	Surgery	Vancomycin MIC /DBV MIC	DBV dose regimen (mg)	Combination treatment	Adverse effects	Effectiveness
1/69	EPVE/L	*Enterococcus faecalis*	No	1st ceftriaxone (2) + ampicillin (2)	No	2/-	1500 (day 1), 1500 (day 15)	No	No	Cure of infection.
2/88	NVE/L (Pacemaker wearer)	MRSA	HF, perivalvular abscess, septic embolism in the upper extremity, chronic osteomyelitis and ARF.	1st daptomycin (1) + ceftaroline (1). 2nd daptomycin (2) + linezolid IV (2). 3rd daptomycin (1) + rifampicin IV (1)	No	≤1/0.094	1500 (4 doses every 15 days)	Rifampicin	Impaired renal function.	Cure of infection.
3/78	LPVE/L	MRSA	HF and splenic embolisms.	1st daptomycin (<1) + ceftaroline (<1). CS. daptomycin (4) + ceftaroline (4)	Aortic valve replacement.	≤1/0.064	1000 (day 1)[a]	Rifampicin	No	Cure of infection.
4/66	LPVE/L	*Enterococcus faecalis*	No	1st ceftriaxone (2) + ampicillin (2).	No	2/-	1500 (day 1), 1500 (day 15)	No	No	Cure of infection.
5/87	NVE/L	MSSA	HF and ARF.	1st ceftaroline (1.5) + daptomycin (1.5). 2nd cefazolin (1.5)	No	≤1/-	1500 (day 1), 1500 (day 15)	No	No	Cure of infection.
6/88	NVE/L	*Enterococcus faecalis*	No	1st ceftriaxone (4) + ampicillin (4)	No	2/-	1500 (day 1)	No	No	Cure of infection.
7/83	LPVE/R	MRSA	No	1st vancomycin (<1). 2nd daptomycin (4) + ceftaroline (4)	No	≤1/0.094	1500 (day 1)	Rifampicin	No	Cure of infection.
8/70	LPVE/L	*Staphylococcus caprae* MS	HF, splenic and ocular embolisms and pyomyositis.	1st daptomycin (1) + cloxacillin (1). 2nd daptomycin (2) + rifampicin IV (2). 3rd ceftaroline (1) + rifampicin IV (1). OS. 4th ceftaroline (2) + fosfomycin (2) + ciprofloxacin IV (1). 5th vancomycin (2)	Muscle abscess drainage.	≤1/-	1000 (day 1), 500 (day 8)	No	No	Cure of infection.
9/90	LPVE/L	*Staphylococcus capitis* MR	HF	1st daptomycin (2) + ceftaroline (2). 2nd daptomycin (1) + fosfomycin (1).3rd daptomycin (1)	No	≤1/-	1000 (day 1), 500 (day 8), 1500 (day 15)	Rifampicin	No	Cure of infection.

10/77	NVE/R	MSSA	No	1st daptomycin (<1) + ceftaroline (<1). 2nd cefazolin (4) + linezolid IV (2)	No	≤1/-	1500 (day 1)	No	No	Cure of infection.
11/92	NVE/L (Pacemaker wearer)	*Streptococcus gallolyticus*	HF, splenic embolisms, and spondylodiscitis.	1st vancomycin (<1). 2nd ceftriaxone (4)	No	0.5/-	1500 (day 1)	Rifampicin	No	Clinical failure. Death related to IE in follow-up.
12/65	LPVE/L	*Streptococcus salivarius*	No	1st ceftriaxone (4) + gentamicin (1.5)	No	1/-	1500 (day 1)	No	No	Cure of infection.
13/71	NVE/L	*Staphylococcus haemolyticus* MS	No	1st daptomycin (1) + cloxacillin (1). CS. 2nd cloxacillin (3). 3rd cefazolin (1)	Aortic and mitral valve replacement.	≤1/0.094	1500 (day 1), 1000 (day 15)	No	No	Cure of infection.
14/94	NVE/L	Without microbiological isolation[b]	Hepatic abscess, pulmonary infiltrates (eosinophilic daptomycin pneumonia) and ARF.	1st ceftriaxone (<1). 2nd ertapenem (1). 3rd meropenem (1). 4th daptomycin (2) + ceftriaxone (2). 5th ceftriaxone (3) + linezolid IV (3)	No	-	1500 (day 1)	Cefditoren	No	Clinical failure. Death at EOT.
15/81	LPVE/L	MSSA	HF and persistent bacteraemia (>1 week).	1st cloxacillin (1.5) + daptomycin (1.5). 2nd ceftaroline (1) + rifampicin IV (1). 3rd cloxacillin (3) + rifampicin IV (3)	No	≤1/-	1500 (day 1)	Rifampicin	No	Cure of infection.
16/82	IDE (Pacemaker)	MSSA	No	1st cloxacillin (1) + daptomycin (1). CS. 2nd cloxacillin (3) + rifampicin IV (3)	Pacemaker removal and implantation.	≤1/-	1000 (day 1)[a]	Rifampicin	No	Cure of infection.
17/62	NVE/L	MSSA	Perivalvular abscess, splenic, ocular, and cerebral embolisms, septic arthritis, and cerebral haemorrhage.	1st cloxacillin (1.5) + daptomycin (1.5). CS. cloxacillin (4) + daptomycin (2)	Aortic valve replacement.	≤1/-	1000 (day 1)[c]	Rifampicin	Thrombopenia with epistaxis	Clinical failure. Death (nosocomial pneumonia) in the follow-up.
18/87	IDE (Pacemaker)	MSSA	Septic embolism in the upper extremity and VT	1st cloxacillin (1) + daptomycin (1). CS. 2nd cloxacillin (3) + rifampicin IV (2) + daptomycin (1)	Pacemaker removal and implantation.	≤1/-	1500 (day 1)	No	No	Cure of infection

19/70	LPVE/L (VAT)	MSSA	Septic shock, splenic, cerebral, and ophthalmic embolisms, ischemic ictus and ARF.	1st cloxacillin (6) + daptomycin (6) + rifampicin IV (5). 2nd linezolid OR (2)	No	≤1/-	1000 (day 1), 500 (day 8), 1500 (every 15 days up to complete 6 months)	Rifampicin	No	Cure of infection
20/85	NVE/L	*Staphylococcus epidermidis* MR	No	1st vancomycin (2)	No	≤1/0.004	1500 (day 1) and 2 weeks with rifampicin OR.	No	No	Cure of infection
21/77	IDE (Pacemaker)	MRSA	No	1st daptomycin (2) + fosfomycin (1)	No	≤1/0.094	1500 (day 1), 1500 (day 15)	Rifampicin	No	Clinical failure. Death (complicated urinary infection related to permanent urinary catheter in a frail elderly patient) in the follow-up.
22/66	EPVE/L	*Streptococcus gordonii*	Septic shock, HF, VT perivalvular abscess, hepatic and ophthalmic embolisms, spondylodiscitis, epidural abscess, bursitis and ARF.	1st ceftriaxone (1.5). CS (A). 2nd ceftriaxone (1.5) + linezolid IV (1.5). CS (B). ceftriaxone (2) + linezolid IV (1). 4th ceftriaxone (2) + levofloxacin (2) IV. OS (C). 5th Imipenem/cilastatin (4)	A. Aortic valve replacement with valve tube and pacemaker implantation. B. Pacemaker replacement due to malfunctioning. C. Abscess drainage and lumbar arthrodesis	0.5/-	1500 (day 1)	No	No	Cure of infection.
23/76	NVE/L	MRSA	Spondylodiscitis, epidural, paravertebral and spinal abscesses. Myositis, bursitis,	1st daptomycin (3) + ceftaroline (3). 2nd ceftaroline (5) + clindamycin (1)	No	≤1/-	1500 (day 1), 1500 (day 15)	No	No	Cure of infection.

			shoulder abscess and osteomyelitis.							
24/79	LPVE/L	MSSA	Septic shock, HF, and cutaneous embolisms.	1st vancomycin (<1). 2nd cloxacillin (1) + daptomycin (1). CS. 3rd ceftaroline (4) + fosfomycin (2) + rifampicin IV (3)	Aortic valve replacement.	≤1/0.094	1500 (day 1)	Rifampicin	No	Cure of infection.
25/64	IDE (DAI)	MRSA	Septic arthritis and osteomyelitis.	1st daptomycin (3). 2nd ceftaroline (2). CS. ceftaroline (1)	DAI removal and replacement.	2/0.064	1500 (day 1)	No	No	Cure of infection.
26/66	EPVE/R	MSSA	Ischemic ictus and leukocytoclastic vasculitis.	1st cefazolin (1.5) + linezolid (1.5). 2nd daptomycin (5.5) + rifampicin IV (5.5)	No	≤1/0.125	1500 (day 1)	Rifampicin	No	Cure of infection.
27/65	NVE/L	*Enterococcus faecium*	No	1st Imipenem/cilastatin (4) + fosfomycin (4) + tedizolid OR (2). CS. 2nd ceftaroline (6) + ampicillin (6)	Aortic valve replacement.	2/0.125	1500 (day 1)	No	No	Cure of infection.
28/90	NVE/L	*Enterococcus faecalis*	Splenic embolism.	1st ceftriaxone (2) + ampicillin (2). 2nd daptomycin (<1) + fosfomycin (<1)	No	1/-	1500 (day 1), 1500 (day 15)	No	No	Clinical failure Death (bronchoaspirative pneumonia) in the follow-up.
29/93	NVE/L + IDE (Pacemaker)	*Enterococcus faecalis*	HF and splenic embolisms.	1st ceftriaxone (6) + ampicillin (6)	No	2/-	1500 (day 1)	No	No	Clinical failure Death at EOT.
30/73	NVE/L	MSSA	HF, cerebral embolisms, ischemic ictus and ARF.	1st ceftaroline (3) + daptomycin (3). 2nd ceftaroline (1). 3rd cefazolin (2)	No	≤1/-	1500 (day 1)	No	No	Cure of infection.
31/65	EPVE/L	MRSA	HF and ischemic ictus.	1st daptomycin (<1) + ceftaroline (<1). 2nd daptomycin (1.5) + ceftaroline (1.5) + fosfomycin (1.5). CS. 3rd ceftaroline (2) + linezolid (2)	Aortic and mitral valve replacement.	≤1/-	1500 (day 1), 1500 (day 15)	No	No	Clinical failure Death (cerebral haemorrhage secondary to acenocoumarol) in the follow-up.
32/60	NVE/R	MSSA	Septic arthritis, lumbar abscess and pyomyositis.	1st daptomycin (2) + cloxacillin (2). 2nd cefazolin (1) + rifampicin	Lumbar laminectomy and	≤1/-	1500 (day 1), 1500 (day 15)	No	No	Cure of infection.

				IV. OS. 3rd cefazolin (4) + rifampicin IV (4).	drainage of epidural and lumbar abscess					
33/52	NVE/L	MSSA	Septic shock, HF, septic arthritis and pyomyositis.	1st ceftaroline (1) + daptomycin (1). CS. ceftaroline (2) + daptomycin (2). OS. 2nd cefazolin (2).	CS. Aortic valve replacement. OS. Muscle abscess drainage.	≤1/-	1500 (day 1).	Rifampin	No	Cure of infection.
34/87	NVE/L	MSSA	No	1st ceftaroline (0.5) + daptomycin (0.5). 2nd cefazolin (2)	No	≤1/-	1500 (day 1) and 2 weeks with linezolid OR.	No	No	Cure of infection.
35/69	EPVE/L	*Staphylococcus haemolyticus* MR	No	1st ceftaroline (1) + daptomycin (1)	No	≤1/0.125	1500 (day 1), 1500 (day 15), 1500 (day 30).	No	No	Cure of infection.
36/81	LPVE/L	*Enterococcus faecalis*	ARF	1st ceftriaxone (4) + ampicillin (4).	No	2/-	1000 (day 1)[a]	No	No	Cure of infection.
37/44	NVE/R	MRSA	Pulmonary embolisms.	1st ceftaroline (2) + daptomycin (2).	No	≤1/0.032	1500 (day 1), 1500 (day 15).	No	No	Cure of infection.
38/91	LPVE/L	*Enterococcus faecalis*	HF and ischemic stroke.	1st daptomycin (2) + imipenem/cilastatin (2)	No	2/-	1500 (day 1), 1500 (day 15).	No	No	Clinical failure. Relapse and death related to IE in follow-up.
39/55	LPVE/L	*Enterococcus faecalis*	No	1st ceftriaxone (3.5) + ampicillin (3.5).	No	2/-	1500 (day 1) and half week with linezolid OR.	No	No	Cure of infection.
40/60	NVE/R	*Enterococcus faecalis*	HF and ARF.	1st daptomycin (1) + imipenem/cilastatin (1). 2nd ceftriaxone (2) + ampicillin (2). 3rd daptomycin (1) + imipenem/cilastatin (1).	No	2/-	1500 (day 1).	No	No	Clinical failure Death related to IE in follow-up.
41/67	NVE/L	*Enterococcus faecalis*	No	1st ceftriaxone (0.5) + ampicillin (0.5). CS. 2nd ceftriaxone (2) + ampicillin (2).	Aortic valve replacement.	2/-	1500 (day 1), 1500 (day 15).	No	No	Cure of infection

42/75	NVE/L	MRSA	Embolism in the right upper extremity.	1st ceftaroline (2) + daptomycin (2). 2nd daptomycin (2)	Aortic valve replacement.	≤1/0.064	1500 mg (day 1).	No	No	Cure of infection
43/89	NVE/L	*Enterococcus faecalis*	Spondylodiscitis.	1st ceftriaxone (1) + ampicillin (1). CS. 1st ceftriaxone (3) + ampicillin (3).	No	2/-	1500 (day 1).	No	No	Cure of infection
44/75	NVE/L	*Enterococcus faecalis*	No	1st ceftriaxone (3.5) + ampicillin (3.5). CS[d]	Aortic valve replacement	1/-	1500 (day 1).	No	No	Cure of infection
45/88	IDE (Pacemaker)	*Staphylococcus warneri MS*	AFR	1st cefazolin (3)	No	2/0.125	750 (day 1)[a]	No	No	Cure of infection
46/89	LPVE/L	*Enterococcus faecalis and Streptococcus lugdunensis*	HF	1st ceftriaxone (3.5) + ampicillin (3.5).	No	2 and 0.5/0.004 and 0.064	1500 (day 1), 1500 (day 15).	No	No	Cure of infection
47/90	NVE/L	*Staphylococcus epidermidis* MR	HF and ARF	1st daptomycin (1) + ceftaroline (1). 2nd daptomycin (1)	No	2/0.125	1500 (day 1).	No	No	Clinical failure. Relapse
48/82	NVE/L	*Enterococcus faecalis*	Leukocytoclastic vasculitis.	1st ceftriaxone (2) + ampicillin (2).	No	2/-	1500 (day 1), 1500 (day 15).	No	No	Clinical failure. Death at EOT.

IE, infective endocarditis; DBV, dalbavancin; MIC, minimum inhibitory concentration; CCI, Charlson comorbidity index; HF, heart failure; ARF, acute renal failure; CS, cardiac surgery; OS, other surgery; MSSA, methicillin-sensitive *S. aureus*; MRSA, methicillin-resistant *S. aureus*; MR, methicillin-resistant; MS, methicillin-sensible; LPVE, late prosthetic valve endocarditis; EPVE, early prosthetic valve endocarditis; NVE, native valve endocarditis; IDE, intracardiac device endocarditis; VAT, valve aortic tube; ICD, implantable cardioverter-defibrillator; L, left; R, right; OR, oral; IV, intravenous; VT, ventricular tachycardia.

[a]dose adjusted to renal function.

[b]decapitated by previous antibiotic therapy.

[c]withdrawal due to adverse effects.

[d]cardiac surgery was performed 3 months after DBV administration due to severe aortic insufficiency.